Emflaza Approval History
FDA Approved: Yes (First approved February 9, 2017)
Brand name: Emflaza
Generic name: deflazacort
Dosage form: Tablets and Oral Suspension
Company: PTC Therapeutics, Inc.
Treatment for: Duchenne Muscular Dystrophy
Emflaza (deflazacort) is a glucocorticoid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Development History and FDA Approval Process for Emflaza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.